[{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nilvadipine","moa":"L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roskamp Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp Institute \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Nilvadipine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Roskamp Institute

                          Country arrow
                          euroPLX 86 Munich
                          Not Confirmed

                          Roskamp Institute

                          Country arrow
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The data from the trial showed that early-stage Alzheimer’s patients who were taking Nilvadipine showed less cognitive decline over an 18-month period than patients treated with placebo.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 06, 2020

                          Lead Product(s) : Nilvadipine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank